Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN
Replimune Inc.
Replimune Inc.
Eastern Cooperative Oncology Group
Icahn School of Medicine at Mount Sinai
Actuate Therapeutics Inc.
Odense University Hospital
Incyte Corporation
Bristol-Myers Squibb
Centre Antoine Lacassagne
University of Michigan Rogel Cancer Center
Mateon Therapeutics